{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:06:33Z","timestamp":1761998793900,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.idcr.2020.e00706","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T02:44:56Z","timestamp":1580265896000},"page":"e00706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intravenous (IV) cefazolin with oral probenecid: A novel daily regimen for the management of Methicillin Sensitive Staphylococcus aureus (MSSA) bacteremia in a patient with renal dysfunction"],"prefix":"10.1016","volume":"19","author":[{"given":"Sunish","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Golden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Topal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayna","family":"McManus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.idcr.2020.e00706_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"January (1)","key":"10.1016\/j.idcr.2020.e00706_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idcr.2020.e00706_bib0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archinternmed.2011.1027","article-title":"Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008","volume":"172","author":"Federspiel","year":"2012","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.idcr.2020.e00706_bib0020","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.idcr.2020.e00706_bib0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2020.e00706_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","article-title":"Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia","volume":"15","author":"Wong","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.idcr.2020.e00706_bib0035","first-page":"238","article-title":"Probenecid as an adjuvant in the treatment of gonorrhea with penicillin","volume":"39","author":"Jensen","year":"1963","journal-title":"Br J Vener Dis"},{"issue":"1","key":"10.1016\/j.idcr.2020.e00706_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"10.1016\/j.idcr.2020.e00706_bib0045","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.1093\/infdis\/128.Supplement_2.S399","article-title":"Cefazolin in the treatment of gonorrhea","volume":"128","author":"Karney","year":"1973","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.idcr.2020.e00706_bib0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.4.3.366","article-title":"Pharmacodynamics of cefazolin in the presence of normal and impaired renal function","volume":"4","author":"Rein","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idcr.2020.e00706_bib0055","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/infdis\/130.4.398","article-title":"Treatment of gonorrhea with cefazolin plus probenecid","volume":"130","author":"Duncan","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idcr.2020.e00706_bib0060","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/jac\/31.6.1009","article-title":"The effect of probenecid on cefazolin serum concentrations","volume":"31","author":"Brown","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl","key":"10.1016\/j.idcr.2020.e00706_bib0065","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/infdis\/128.Supplement_2.S341","article-title":"Pharmacokinetics of cefazolin compared with four other cephalosporins","volume":"128","author":"Kirby","year":"1973","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.idcr.2020.e00706_bib0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0736-4679(96)00126-6","article-title":"Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections","volume":"14","author":"Brown","year":"1996","journal-title":"J Emerg Med"},{"issue":"11","key":"10.1016\/j.idcr.2020.e00706_bib0075","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1086\/340056","article-title":"Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults","volume":"34","author":"Grayson","year":"2002","journal-title":"Clin Infect Dis"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250920300147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250920300147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:02:14Z","timestamp":1761998534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250920300147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":15,"alternative-id":["S2214250920300147"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2020.e00706","relation":{},"ISSN":["2214-2509"],"issn-type":[{"type":"print","value":"2214-2509"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous (IV) cefazolin with oral probenecid: A novel daily regimen for the management of Methicillin Sensitive Staphylococcus aureus (MSSA) bacteremia in a patient with renal dysfunction","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2020.e00706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e00706"}}